Cybin announces renewed at-the-market equity program of up to us$35 million

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today that it has renewed its previously established at-the-market equity program (the “atm program”) that allows cybin to issue and sell up to us$35,000,000 of common shares (“shares”) in the capital of the company from treasury to.
CYBN Ratings Summary
CYBN Quant Ranking